Amphastar Pharmaceuticals, Inc. — Earnings Quality Grade F
AMPH · Healthcare
Major red flags
Screening Summary
管理层信号
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 73 days, change +5 days YoY
AR outpaced revenue for 2 consecutive years
Revenue -1.7%, CFFO -26.8%. Cash follows revenue
Expense Quality
Inventory 15.1% vs COGS 1.6%. Normal
CapEx growth -9.5% vs revenue -1.7%. Normal
SG&A/Gross Profit = 36.5%. Normal
Gross margin 49.5%, change -1.6pp. Stable
Cash Flow Quality
CFFO/NI = 1.59. Profits backed by cash
FCF $0.1B, FCF/NI = 1.21
Accruals ratio = -3.6%. Low accruals
Cash $0.3B covers only 43% of debt $0.7B
Balance Sheet Health
Goodwill+Intangibles $0.6B = 72% of equity. Over 50%
Debt/EBITDA = 3.1x. Healthy
Other assets 19.8% vs revenue -1.7%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions positive
Goodwill+Intangibles change -4% YoY. Normal
Manipulation Score
M-Score = -2.69 (< -2.22). Unlikely manipulator
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25